Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-020473
Filing Date
2025-02-14
Accepted
2025-02-14 08:58:10
Documents
76
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q neup-20241231.htm   iXBRL 10-Q 1735136
2 EX-31.1 neup-ex31_1.htm EX-31.1 19995
3 EX-31.2 neup-ex31_2.htm EX-31.2 19967
4 EX-32.1 neup-ex32_1.htm EX-32.1 10667
5 EX-32.2 neup-ex32_2.htm EX-32.2 12539
  Complete submission text file 0000950170-25-020473.txt   6680404

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT neup-20241231.xsd EX-101.SCH 894071
79 EXTRACTED XBRL INSTANCE DOCUMENT neup-20241231_htm.xml XML 1045509
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-41157 | Film No.: 25623629
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)